Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind trial of an 11-valent recombinant HPV vaccine in Chinese women
CTR20201029Phase 2Completed
- Sponsor
- Sinopharm
- Start
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 11-valent recombinant human papilloma virus vaccine in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), cervical carcinoma in situ, Cervical Cancer (CC), anogenital warts, sponsored by Sinopharm. Started Jul 2020; status: completed.
02
Drugs
11-valent recombinant human papilloma virus vaccine
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)cervical carcinoma in situCervical Cancer (CC)anogenital warts
Beyond the preview
Go deeper on CTR20201029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201029.